Drug intelligence / Profile preview

EG-COVID

Development stage: Phase 2
Lead developer: EyeGene
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

EG-COVID is an mRNA-based vaccine candidate developed for the prevention of COVID-19. It utilizes messenger RNA encoding the spike protein of SARS-CoV-2, delivered via a lipid nanoparticle system. The vaccine is designed to induce an immune response by instructing cells to produce the viral spike protein, thereby stimulating both humoral and cellular immunity against SARS-CoV-2 infection. The primary indication for EG-COVID is prophylaxis against COVID-19.

Brand names: EG-COVID
Other names: EG-COVID

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on EG-COVID.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EG-COVID.

Explore the full profile